Clinical Research Directory

Inclusion Criteria: 1. Have fully understood this study and voluntarily signed the ICF, willing to complete the planned visits, treatments, procedures, and laboratory tests during the study period; 2. Age ≥18 years old; 3. Patients with grade 2 oligodendroglioma or grade 2 astrocytoma; 4. Have confirmed presence of IDH1 or IDH2 gene mutation, and obtained chromosome 1p/19q status; 5. Have undergone at least 1 glioma surgery and have not received any other anti-glioma treatments, including chemotherapy and radiotherapy; 6. Confirmed by BIRC, at least 1 measurable non-enhancing lesion meeting RANO 2.0 criteria using two-dimensional magnetic resonance imaging (MRI) measurement at screening; 7. KPS ≥80; 8. As judged by the investigator, life expectancy of ≥12 months; 9. Adequate bone marrow, hepatic, renal, and coagulation function Exclusion Criteria: 1. Previously received any other anti-glioma treatment except for surgery, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or biological therapy, etc.; 2. Participants assessed by the investigator as having high-risk factors, including but not limited to tumor involvement of the brainstem, or uncontrolled epilepsy; 3. Participants with concurrent other malignant tumors or a history of other malignant tumors within 5 years prior to randomization (excluding cured basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast, etc.); 4. Women who are pregnant (positive pregnancy test before medication) or breastfeeding; 5. Known allergy to any component of HMPL-306; 6. Administration of uridine diphosphate glucuronosyltransferase (UGT) 1A1 inhibitors or UGT1A3 inhibitors less than 1 week or 5 half-lives (whichever is longer) prior to randomization; administration of strong inducers of CYP3A less than 2 weeks or 5 half-lives (whichever is longer) prior to randomization; 7. Presence of diseases or conditions that affect drug absorption; 8. Participants will be excluded if there is any other disease, mental abnormality, metabolic abnormality, physical examination abnormality, or laboratory parameter abnormality of significant clinical significance, etc., which, in the investigator's judgment, may affect the participant's compliance, or place the participant at high risk, or affect the interpretation of study results, or if there is reason to suspect that the participant has a disease or condition unsuitable for the use of the study drug.